NOCIL Guides FY27 Revenue Rs 1,400–1,600 Crores, EBITDA ~10%

NOCIL Limited — Q1 FY27 Earnings Call (Quarter ended 30 June 2026)

1. Overall Tone of Management: Optimistic

• Management highlights strong growth and margin expansion: “revenue… Rs. 403 crores… 20% YoY growth” and “EBITDA… Rs. 45 crores… EBITDA margins… 11.2%.”
• Despite operational disruptions, they frame them as temporary/supply-side: “temporary supply-side constraints… underlying customer demand remaining healthy.”
• They end with positive guidance and confidence: “we are optimistic… We expect revenue for FY’27… Rs 1,400 to Rs 1,600 crores… with EBITDA… ~10%.”

2. Key Themes from Management Commentary

• Demand resilience + pricing support
• “sustained demand across key end markets”
• revenue growth attributed to “growing volumes and increase in selling prices on account of increase in raw material costs.”
• Operational disruptions are supply-side, not demand-side
• sequential volume down “primarily due to temporary supply-side constraints related to utilities and logistical challenges.”
• management expects “recovering the deferred volumes in the coming quarters.”
• Anti-dumping duty progress (policy tailwinds)
• Central Government approved anti-dumping duty on Sulphonamides (CBS & NS) effective 20 June 2026.
• DGTR issued positive final recommendation for Pilflex 13; implementation pending government approval.
• TDQ Dahej plant ramp-up
• “trial production… coming along well… initiation of samples to customers.”
• “new Rs 130 crore investment… progressing well… keeping it on track.”
• FY27 outlook anchored on EBITDA ~10%
• guidance ties performance to “operating excellence… expanding our product portfolio… prudent financial management.”

3. Q&A Analysis

Theme A: EBITDA sustainability, run-rate, and cost normalization

• Core questions
• Whether Q1 EBITDA run-rate (~11.2% margin) is sustainable and how much is driven by one-offs.
• What drives sequential increase in conversion cost (conversion cost Rs. 110 cr → Rs. 130 cr).
• Management response
• EBITDA expected to “hover around 10% of EBITDA” for the year.
• Conversion cost increase explained as one-offs: logistics/freight inflation from “Middle East war crisis,” higher CSR spend in Q1, utilities/gas constraints, stock change effect, and maintenance issues.
• Employee cost expected to “stabilize”; utility cost to reduce if oil price stabilizes; maintenance cost “one-time.”
• Assessment
• Partially evasive on quantification: asked to quantify one-off cost; management gave qualitative drivers and “a few crores” type language, not a clean number.

Theme B: TDQ plant approvals timeline and revenue/volume contribution

• Core questions
• When customer approvals translate into material volumes (Q4 vs Q1 next year).
• Whether TDQ can lift run-rate to higher index levels (160–165 in Q4 FY27).
• Whether TDQ revenues will come in FY27 and utilization ramp.
• Management response
• Approvals typically “six to eight months… start trickling in Quarter 4… more into… Quarter 1 of next year.”
• TDQ revenues: “Yes, there will be revenues coming in this year.”
• Ramp sequencing: start with “non-tyre… domestic as well as international,” then “gradually tyre companies… next couple of quarters.”
• Assessment
• Clear timeline but no hard volume targets for TDQ; indexation target (160–165) was not directly confirmed.

Theme C: FY27 volume growth assumptions and whether guidance was revised

• Core questions
• Given sequential volume dip and prior expectations, is FY27 volume growth (10%) revised down due to geopolitics?
• Mix of domestic vs export volumes.
• Management response
• “We have not… scaled down… still… 10% growth rate.”
• Non-tyre segment saw temporary contraction; tyre demand remains robust.
• Export/domestic mix in Q1: “exports about roughly 33% and domestic 67%.”
• Assessment
• Strong reassurance on guidance not being revised; however, they attribute softness to segment-specific temporary issues rather than broader demand.

Theme D: Anti-dumping duty impact on realizations/EBITDA and timing

• Core questions
• Realization gain from Sulphonamides ADD in Q1 (and whether any benefit already captured).
• For Pilflex 13 (PX13) and total ADD-covered revenue share and expected EBITDA benefit magnitude.
• Why Pilflex 13 was rejected previously and approved now (policy discretion).
• Management response
• For Sulphonamides: “for the quarter ended June… there is no gain there” because duty notified 20 June; impact depends on foreign producers’ absorption.
• ADD-covered top line (excluding TDQ): “25% to 30%.”
• EBITDA benefit: “a bit premature… too premature to comment today.”
• Pilflex 13 approval: government discretion; they are “hopeful” and expect outcome “maybe by the end of September.”
• Assessment
• Notably cautious on quantifying EBITDA uplift; consistent with “foreign players absorb” uncertainty.

Theme E: Antioxidants/TDQ/accelerators competitive dynamics and dumping

• Core questions
• How antioxidants dumping and falling realizations will play out given TDQ ADD not approved earlier.
• Impact of competitor capacity additions (China Sunshine) on accelerators pricing/volumes.
• Management response
• TDQ roadmap includes growth “despite… did not get the anti-dumping.”
• No significant change in import numbers; limited visibility but “do not see a significant increase.”
• For accelerators: they had approached anti-dumping; competitor capacity relates to intermediates; they can compete “with also the anti-dumping duty now that is in place.”
• Assessment
• Some visibility limits (“limited visibility”) and scenario planning language.

Theme F: Other governance/credibility question

• Core question
• Why promoter holdings are being pledged again (~24% pledged).
• Management response
• “We cannot comment… prefer to remain non-committal.”
• Assessment
• Deflection; no explanation provided.

4. Guidance / Outlook

Explicit guidance (quantitative)

• FY27 revenue: Rs. 1,400 to Rs. 1,600 crores
• FY27 EBITDA: ~10%
• FY27 volume growth assumption: ~10% (stated in Q&A)
• Q1 export/domestic mix: exports ~33%, domestic ~67% (not full-year guidance, but a stated mix)

Implicit signals (qualitative)

• EBITDA margin sustainability: expects to “hover around 10%” despite one-offs.
• Demand outlook: “underlying… demand remaining healthy” and “overall demand outlook remains positive.”
• TDQ ramp: approvals “start trickling in Quarter 4,” more material in “Quarter 1 of next year.”
• Raw material/geopolitics: continued uncertainty on “pricing… availability… keep a close watch.”

5. Standout Statements (direct / high-signal)

• Margin/run-rate anchor: “we expect to hover around 10% of EBITDA.”
• Demand vs supply framing: “These challenges were operational in nature rather than demand-driven.”
• One-off cost drivers (conversion cost): logistics/freight inflation from “Middle East war crisis,” utilities/gas constraints, CSR front-loading, maintenance issues.
• TDQ approval timing: “typically about six to eight months… start trickling in Quarter 4… more into Quarter 1 of next year.”
• ADD timing impact: “for the quarter ended June… there is no gain there” (duty notified 20 June).
• ADD-covered revenue share: “totally about 25% to 30%.”
• Export direction: “Directionally… exports… will go” toward higher share (asked about 28–29/40–45% for later years; management agreed directionally).

6. Red Flags / Positive Signals

Red flags
– Limited quantification of one-offs (conversion cost increase): asked for quantification; response stayed qualitative.
– Cautious stance on ADD benefit: repeatedly “premature” / “too premature,” implying uncertainty in realization/EBITDA uplift.
– Promoter pledge question deflected: no rationale provided.
– Sequential volume decline acknowledged (even if supply-side): “moderate decline of 3%” and “postponement of certain order commitments.”

Positive signals
– Strong Q1 profitability improvement: EBITDA up YoY and QoQ; EBITDA margin expanded to 11.2%.
– Clear operational explanations for cost/margin movements (utilities, freight, CSR, maintenance).
– TDQ progress is tangible: samples initiated; investment “on track.”
– Policy tailwinds progressing: Sulphonamides duty approved; Pilflex 13 positive recommendation.

7. Historical Comparison & Consistency Analysis (vs prior calls)

a. Change in Tone Over Time

• Current (Q1 FY27): more optimistic
• Compared with Q4 FY26 and earlier FY26 calls where margins were under pressure and dumping was a key theme, Q1 FY27 shows margin expansion and confident FY27 guidance.
• What changed
• Shift from “pricing under pressure / dumping” narrative (earlier) to “pricing + volume growth” and EBITDA run-rate confidence.
• Still acknowledges geopolitics, but now frames it as operational normalization rather than structural demand weakness.

b. Tracking Past Commitments vs Outcomes

• TDQ Dahej trial/approvals timeline
• Prior (Q4 FY26, May 2026): TDQ capex completed; “commenced trial production… samples… approval.”
• Current (Q1 FY27): “trial production… coming along well with initiation of samples to customers.”
• Status: ✅ Consistent / on track (no major slippage stated).
• Cost initiatives / conversion cost improvement
• Prior (Q4 FY26): conversion/utility and efficiency initiatives were expected to improve margins.
• Current: conversion cost increased sequentially due to one-offs, but management claims stabilization and one-time nature.
• Status: ⏳ Mixed—directionally consistent (efficiency story persists) but Q1 shows temporary deterioration.
• ADD timing expectations
• Prior (Q2 FY26 / Q3 FY26): ADD investigations expected in coming months; management often said “premature to quantify.”
• Current: Sulphonamides duty approved; management says no immediate gain in Q1 due to notification date.
• Status: ✅ Mechanically consistent (timing explains lack of immediate benefit), but benefit quantification remains deferred.

c. Narrative Shifts

• From “dumping pressure suppressing margins” → “margin recovery with pricing + operating leverage”
• Earlier calls emphasized dumping and margin compression; now EBITDA margin expansion is highlighted.
• Non-tyre weakness becomes a “temporary transitionary element”
• Current: non-tyre demand contraction due to “input costs and shortage of labor.”
• Earlier: non-tyre was discussed more broadly as impacted by macro/competition; now it’s more clearly quarter-specific.

d. Consistency & Credibility Signals

• Medium credibility
• Positives: management provides plausible operational explanations for sequential volume and cost movements; TDQ timeline appears consistent.
• Concerns: recurring pattern of not quantifying key items (one-off cost quantum, ADD EBITDA uplift) and deflecting sensitive governance question (promoter pledge).

e. Evolution of Key Themes

• Demand: Improving/stable (tyre demand “robust”; overall demand outlook “positive”).
• Margins: Improving in Q1, but management still relies on normalization and operating leverage to sustain.
• Geopolitics/logistics: Persistent risk theme, but increasingly treated as timing/operational rather than demand destruction.
• Regulatory (ADD): From “investigation underway” to “duty approved / recommendation positive,” but financial impact remains uncertain.

f. Additional Insights (cross-period intelligence)

• The company’s financial narrative is increasingly anchored on EBITDA ~10% while repeatedly stating that ADD benefits depend on foreign absorption—suggesting that upside may be capped unless foreign producers pass through costs.
• Sequential volume decline (3%) is framed as supply-side; however, management also says “postponement of certain order commitments,” which can become a recurring working-capital/fulfillment risk if disruptions persist.